Table 3.
Lifitegrast Utilization Among Patients with DED
| Year of index treatment initiation, n (% [95% CI]) | |
| 2017 | 9 (1.5 [0.7, 2.8]) |
| 2018 | 281 (46.8 [42.8, 50.9]) |
| 2019 | 310 (51.7 [47.6, 55.7]) |
| Time from DED diagnosis to lifitegrast initiation, months, mean ± SD [median] (95% CI of mean)a | |
| Overall | 23.3 ± 42.7 [11.6] (19.8, 26.9) |
| Index treatment initiation in 2017 (n=8) | 31.5 ± 55.0 [6.7] (not reported) |
| Index treatment initiation in 2018 (n=265) | 23.8 ± 35.3 [12.0] (19.5, 28.0) |
| Index treatment initiation in 2019 (n=285) | 22.7 ± 48.4 [10.0] (17.0, 28.3) |
| Prescription/Pack prescribed for first prescription | |
| Days’ supply | |
| Mean ± SD [median] (95% CI of mean) | 59.7 ± 37.2 [30.0] (56.5, 62.8) |
| Unknown, n (% [95% CI]) | 60 (10.0 [7.7, 12.7]) |
| Number of refills | |
| Mean ± SD [median] (95% CI of mean) | 4.8 ± 3.0 [4.0] (4.6, 5.1) |
| Unknown, n (% [95% CI]) | 34 (5.7 [4.0, 7.8]) |
| Number of patients with at least 6 months of follow-up, n (% [95% CI]) | 554 (92.3 [89.9, 94.3]) |
| Patients with ongoing lifitegrast treatment at 6-months post-index, n (% [95% CI]) | |
| Overall | 512 (92.4 [89.9, 94.5]) |
| Index treatment initiation in 2017 (n=8) | 8 (100.0 [63.1, 100.0]) |
| Index treatment initiation in 2018 (n=267) | 241 (90.3 [86.1, 93.5]) |
| Index treatment initiation in 2019 (n=279) | 263 (94.3 [90.9, 96.7]) |
| Number of patients with at least 12 months of follow-up, n (% [95% CI]) | 281 (46.8 [42.8, 50.9]) |
| Patients with ongoing lifitegrast at 12-months post-index, n (% [95% CI]) | |
| Overall | 238 (84.7 [79.9, 88.7]) |
| Index treatment initiation in 2017 (n=8) | 8 (100.0 [63.1, 100.0]) |
| Index treatment initiation in 2018 (n=235) | 195 (83.0 [77.6, 87.6)] |
| Index treatment initiation in 2019 (n=38) | 35 (92.1 [78.6, 98.3]) |
| Number of patients who discontinued lifitegrast, n (% [95% CI]) | 76 (12.7 [10.1, 15.6]) |
| Treatment duration, months, mean ± SD [median] (95% CI of mean) | 5.5 ± 3.8 [5.0] (4.7, 6.4) |
| Treatment duration, n (% [95% CI]) | |
| 0 to ≤3 months | 24 (31.6 [21.4, 43.3]) |
| >3 to ≤6 months | 20 (26.3 [16.9, 37.7]) |
| >6 to ≤9 months | 16 (21.1 [12.5, 31.9]) |
| >9 months | 16 (21.1 [12.5, 31.9]) |
| Reasons for treatment discontinuation, n (% [95% CI])b | |
| Insufficient response | 34 (44.7 [33.3, 56.6]) |
| Intolerance of treatment | 25 (32.9 [22.5, 44.6]) |
| Patient preference | 22 (28.9 [19.1, 40.5]) |
| Issue with insurance coverage | 18 (23.7 [14.7, 34.8]) |
| Other | 8 (10.5 [4.7, 19.7]) |
| Unknown | 3 (3.9 [0.8, 11.1]) |
Notes: aForty two patients were missing information on the date of DED diagnosis and were excluded from the calculation. bReasons for treatment discontinuation were calculated among the 76 patients who discontinued treatment with lifitegrast. Patients could have ≥1 reason for index treatment discontinuation. Therefore, the sum of percentages may exceed 100%. Other reasons for discontinuing lifitegrast included out of pocket cost, developed cyst, symptom resolution, sign resolution, and bad taste.
Abbreviations: CI, confidence interval; DED, dry eye disease; NR, not reached; SD, standard deviation.